CTRI/2024/06/068460尚未招募Unknown
To study the outcomes of ocular trauma in terms of visual disability and its effect on the social, economic and psychological aspect among patients Surviving with the traumatic eye. - NI
Department of Ophthalmology SMS Medical college Jaipur0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Patients with ocular injuries (only globe involving injuries) reporting to the casualty and the ophthalmology OPD and treated at department and agrees to give written consent
- •2. Patients of all ages who can understand the questionnaire and can reply.
排除标准
- •1. Those having preexisting vision-threatening ocular diseases like glaucoma, age-related macular degeneration, etc.
- •2. Injury in blind or atrophic eye.
- •3. Comatose or unconscious patients.
- •4. Patients who do not agree to attend regular follow-ups or not ready to reply the questionnaire.
研究者
相似试验
已完成
不适用
Evaluation of Cause and Prognosis in Eyes Requiring Implantable Collamer Lens Extraction.myopiaJPRN-UMIN000040323Kitasato Univ Hospital7
招募中
不适用
Evaluation of ocular pathological condition using polarization-sensitive optical coherence tomographyGlaucoma, Glaucoma after trabeculectomy, Keratoconus, Corneal dystrophy, Pterygium, Inflammatory anterior eye diseases, CataractJPRN-UMIN000014774Department of Ophthalmology, Tohoku University Graduate School of Medicine180
尚未招募
Unknown
Visual disturbances of patients following operatioCTRI/2023/03/050562GCS medical college and hospital
尚未招募
不适用
A study to measure pressure changes in eye while a person undergoes surgery for spine fracture lying on his back during surgeryCTRI/2019/01/017211Department of Anaesthesiology
进行中（未招募）
1 期
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha ExpressioRecurrent Ovarian Cancer with High Folate Receptor-Alpha ExpressionCTIS2023-505617-24-00Immunogen Inc.87